S*BIO has taken a significant step forward in its drug discovery and development efforts as its lead clinical candidate for cancer moves toward clinical trials. The drug, SB939, is Singapore's first homegrown cancer therapy.
S*BIO anticipates that clinical trials of SB939 will commence both in Singapore and in North America in the first quarter of 2007.
In preclinical studies, SB939 has demonstrated anticancer efficacy and has the potential to be used as an oral therapy for a variety of human hematological malignancies and solid tumors.
SB939 belongs to a series of targeted small molecule based anticancer agents that inhibit histone deacetylases, enzymes that are important regulators of pro-apoptotic factors and proteins involved in cell cycle progression and differentiation.